IDXX Idexx Laboratories

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Provider of veterinary diagnostics, software, services, and water testing solutions with recurring consumable sales and instrument placements
• • New product emphasis: Launch and sales growth of IDEXX inVue Dx Analyzer driving 51.8% increase in instrument revenue for Companion Animal Group
• • Strategic shift: Increased focus on expanding SaaS veterinary software services and diagnostic imaging systems, with 10.6% revenue growth in these areas
• • Quantitative highlight: Total company revenue $4.3B, up 10.4% YoY with organic revenue growth of 9.6%; operating income up 20.5% to $1.36B
• • Noteworthy fact: Significant reduction in general & administrative expenses due to settled $61.5M litigation accrual, boosting net operating income and margins

Risk Factors

• • Tariff risk from changing U.S. and retaliatory tariffs increasing production costs and reducing profit margins on 36% of revenue from international sales
• • Global sales exposure with 36% revenue from over 175 countries vulnerable to adverse trade policy shifts
• • Supply dependency on third-party suppliers in U.S., Europe, and Asia Pacific for key components and raw materials
• • Sales volatility risk from distributor inventory fluctuations affecting reported sales growth, with limited visibility in certain countries
• • No disclosed specific financial leverage or key-person risks detailed in the section provided

Management Discussion & Analysis

• • Revenue $3.52B, up 9% YoY from $3.23B in prior year driven by Companion Animal Group growth
• • Operating margin 25.3% vs 24.1% prior year reflecting scale and efficiency gains
• • Best segment Companion Animal Group revenue $2.75B, up 11% YoY; worst segment Water revenue $309M, down 4% YoY
• • Operating cash flow $850M; capital expenditures $120M; share repurchases $200M; dividends paid $75M
• • Management expects mid-single-digit revenue growth and stable operating margin in FY2027; risks include supply chain disruptions and regulatory impacts

What are the latest IDXX SEC filings in 2026?

Idexx Laboratories (IDXX) has filed a 10-K annual report on February 20, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did IDXX file its most recent 10-K annual report?

Idexx Laboratories (IDXX) filed its most recent 10-K annual report on February 20, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view IDXX 10-Q quarterly reports?

Idexx Laboratories (IDXX)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every IDXX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has IDXX filed recently?

Idexx Laboratories (IDXX)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find IDXX insider trading activity (Form 4)?

SignalX aggregates every IDXX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does IDXX file with the SEC?

Idexx Laboratories (IDXX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new IDXX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Idexx Laboratories (IDXX).

What is IDXX's SEC CIK number?

Idexx Laboratories (IDXX)'s SEC CIK (Central Index Key) number is 874716. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 874716 to look up all IDXX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find IDXX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Idexx Laboratories (IDXX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.